Source comparison
Combine MK-677 Ipamorelin Synergy Dosing Timing: Comparison
Sequential Single-Pulse 25mg oral, 8 PM 200–300mcg SC, 6–8 AM (10–12 hours post-MK) 180–240% above baseline Sleep quality, recovery studies, body composition research with once-daily injection convenience Optimal for researchers prioritizing compliance. Single
This comparison does not assign a generated winner or score.
- Sequential Single-Pulse
- 25mg oral, 8 PM
- 200–300mcg SC, 6–8 AM (10–12 hours post-MK)
- 180–240% above baseline
- Sleep quality, recovery studies, body composition research with once-daily injection convenience
- Optimal for researchers prioritizing compliance. Single Ipamorelin injection captures the synergistic effect without multiple daily dosing
- Simultaneous Dosing
- 200mcg SC, 8 PM (same time as MK-677)
- 90–120% above baseline
- Protocols where timing flexibility is limited or when testing additive (not synergistic) effects
- Produces GH elevation but misses the sequential pathway activation. Less effective than staggered timing
- Advanced Three-Pulse
- 200mcg SC × 3 (6 AM, 2 PM, 10 PM)
- 240–280% above baseline (sustained throughout 24hr cycle)
- Intensive anabolic research, maximum GH exposure studies, protocols requiring sustained pulsatile rhythm
- Highest total GH exposure but requires strict injection adherence. Best suited for controlled research environments
- MK-677 Monotherapy
- None
- 60–90% above baseline
- Baseline GH studies, oral-only protocols, research comparing continuous vs pulsatile secretion patterns
- Effective for sustained elevation but lacks the amplified pulses that Ipamorelin provides. Useful comparator in dual-arm studies
- Ipamorelin Monotherapy
- 200–300mcg SC × 2–3 daily
- 120–150% above baseline (pulsatile only)
- Pulsatile GH research, protocols avoiding sustained ghrelin activation, studies isolating GHRP-mediated effects
- Produces physiologic pulses without baseline elevation. Useful when MK-677's appetite or glucose effects are contraindications
- The Sequential Single-Pulse protocol represents the practical optimum for most research applications: you achieve 75–85% of the Advanced Three-Pulse protocol's GH elevation with one-third the injection frequency.